Vertiflex Appoints Chief Commercial Officer

Vertiflex Inc., a developer of advanced, minimally invasive interventions for spinal stenosis, has appointed Michael Enxing as vice president and chief commercial officer. Enxing will be responsible for leading all aspects of the company’s sales, marketing, health economics/reimbursement and professional education strategies, related to the launch of the Superion Indirect Decompression System for the treatment of lumbar spinal stenosis.
 
Enxing brings over 20 years of successful global leadership experience in product commercialization in the medical device, spinal and chronic pain fields. Most recently, he served as vice president of sales at Nevro Corporation, where he led the company to impressive growth both internationally and domestically over the previous four years. Prior to Nevro, Enxing served as vice president of sales and marketing for Vertos Medical, and has held various executive positions at Cardiovascular Systems Inc. (formerly Cardio Vascular Solutions); Advanced Neuromodulation Systems Inc. (acquired by St. Jude Medical Inc.); Stryker Corporation; and Tecnol Medical Products Inc. (acquired by Kimberly Clark). Enxing is a graduate of Iowa State University with a bachelor of science degree in communications and focus in business administration.
 
“We are very pleased to have attracted an executive of Michael’s caliber into our organization. Michael is a visionary leader who understands sales and marketing execution, market dynamics, critical organizational metrics, and cultural drivers that deliver team success and ensures the best customer engagement experiences possible,” said Earl R. Fender, president and CEO of Vertiflex. “We are confident that Michael’s track record of significantly scaling businesses, will add considerable value to Vertiflex, our investors, physician providers, and most of all to patients, who will benefit from Superion’s demonstrated and durable clinical and safety profile.”
 
“I’m proud to join the Vertiflex team. As a result of the company’s achievements in product development, Level I clinical evidence generation, earning a PMA approval and Category I reimbursement for Superion, the stage is set to build a large, high growth, new category in spine that is focused on compelling clinical outcomes for patients and their physicians,” Enxing said. “Based on my prior experience in commercializing an early generation product for lumbar spinal stenosis, I believe Superion, having significant published peer-reviewed data, is positioned as the best-in-class minimally invasive solution for lumbar spinal stenosis that will also compare well to open surgical decompression in treating patients suffering from LSS.”
 
Vertiflex is a privately held medical device company dedicated to the advancement of minimally invasive solutions for the treatment of lumbar spinal stenosis, which is the leading cause of spinal surgery in the elderly. Founded in 2005 and headquartered in Carlsbad, Calif., Vertiflex has developed proprietary, minimally invasive technologies for performing both indirect and direct decompressions of the lumbar spine. These procedures fill the gap in the stenosis treatment continuum between conservative care and traditional spine surgery. To date, Vertiflex has compiled the largest, most rigorous body of device clinical evidence related to lumbar spinal stenosis.